These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9028558)

  • 1. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
    Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
    Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
    Beard SM; Lorigan PC; Sampson FC
    Br J Cancer; 2000 Jan; 82(1):81-4. PubMed ID: 10638970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
    Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
    Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting.
    Prajogo J; Neil A; Duke J; Zhang H; Stokes B; Rowlings P
    Intern Med J; 2009 Aug; 39(8):519-26. PubMed ID: 19732200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo.
    Messori A; Bosi A; Bacci S; Laszlo D; Trippoli S; Locatelli F; Van Lint MT; Di Bartolomeo P; Amici A
    Bone Marrow Transplant; 1999 Mar; 23(5):489-95. PubMed ID: 10100564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
    van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
    Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia].
    Uyl-de Groot CA; Rutten FF
    Ned Tijdschr Geneeskd; 1994 Jan; 138(1):28-31. PubMed ID: 8289955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
    Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
    Bolwell B; Goormastic M; Andresen S
    Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
    Hillner BE; Smith TJ; Desch CE
    JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
    Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant.
    Schimmer AD; Dranitsaris G; Ali V; Falconer M; Keating A
    Support Care Cancer; 2002 Apr; 10(3):247-52. PubMed ID: 11904790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.